Fresenius’ mAbxience and HP Develop AI Digital-Twin Platform to Enhance Biopharma Production

Fresenius’ mAbxience and HP Develop AI Digital-Twin Platform to Enhance Biopharma Production

(IN BRIEF) Fresenius’ mAbxience has partnered with HP Inc. to co-develop an AI and digital-twin solution that can model and optimise biopharmaceutical manufacturing. The technology uses real plant data to simulate production scenarios, helping increase reliability, stabilise yields and shorten development cycles for biosimilars and monoclonal antibodies. Following initial validation at mAbxience’s León site, the platform could be expanded to additional facilities. The initiative supports Fresenius’ #FutureFresenius strategy and builds on the company’s strong presence in Spain across Quirónsalud, Fresenius Kabi and biosimilar production.

(PRESS RELEASE) BAD HOMBURG, 4-Dec-2025 — /EuropaWire/ — Fresenius’ biosimilars company mAbxience has entered into a development partnership with HP Inc. to create an artificial-intelligence platform designed to modernise and streamline industrial biomanufacturing. The collaboration combines HP’s digital-twin and data-modelling capabilities with mAbxience’s expertise in monoclonal antibody and biosimilar production, with the aim of improving process predictability, efficiency and product consistency.

Through the joint initiative, the two companies are building an AI tool that can virtually replicate key steps of cell-culture and production workflows. By modelling process conditions, forecasting outcomes and analysing scenarios before they occur on the production line, the system seeks to help teams reduce development time, stabilise yields and better navigate the complexities of large-scale biological manufacturing. The prototype has been developed using real industrial datasets and has already been validated within a live production environment.

This is the first project launched under a broader strategic collaboration framework between mAbxience and HP, centred around mAbxience’s facility in León, Spain, where future roll-outs may follow if the platform scales successfully. For Fresenius, the initiative represents another milestone in building a digitally enabled (Bio)Pharma platform as part of its #FutureFresenius strategy, which focuses on efficiency, innovation and improved access to advanced therapies.

Fresenius footprint in Spain

Spain plays a significant role in Fresenius’ global portfolio. Through Quirónsalud, Spain’s largest private hospital network, and Fresenius Kabi, a supplier of medicines and technologies for patients with critical and chronic conditions, the company contributes to healthcare across the country. The acquisition of mAbxience in 2022 added a fully integrated biosimilars development and manufacturing capability, strengthening Spain as an innovation hub for the group. The collaboration with HP further extends that strategy by embedding digital and AI-supported production pathways into future operations.

Media Contact:

Alexandra Graulich
Secretary Group Communications
T: +49 (0) 6172 608-2501
alexandra.graulich@fresenius.com

SOURCE: Fresenius AG